Wide Ranks

KPTI

Karyopharm Therapeutics Inc.

0.8525

Top Statistics
Market Cap 106 M Forward PE -1.13 Revenue Growth 7.70 %
Current Ratio 3.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -58.93 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.92 Enterprise / Revenue 1.62 Price To Sales Trailing12 Months 0.7197
Profitability
Profit Margins -58.93 % Operating Margins -67.77 %
Balance Sheet
Total Cash 133 M Total Cash Per Share 1.07 Total Debt 267 M
Total Debt To Equity Current Ratio 3.00 Book Value Per Share -1.27
All Measures
Short Ratio 2125.00 % Message Board Id finmb_115373285 Shares Short Prior Month 17 M
City Newton Uuid 5c4cd3b3-c1bf-3bcd-be28-a26f0ffcf89a Previous Close 0.8758
First Trade Date Epoch Utc 1 B Book Value -1.27 Beta 0.1540
Total Debt 267 M Volume 365673 Fifty Two Week Low 0.6170
Total Cash Per Share 1.07 Total Revenue 148 M Shares Short Previous Month Date 1 B
Target Median Price 5.00 Max Age 86400 Recommendation Mean 1.86
Sand P52 Week Change 0.3133 Operating Margins -67.77 % Target Mean Price 4.50
Net Income To Common -87479000 Short Percent Of Float 0.1541 Implied Shares Outstanding 126 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 458970
Average Volume10days 458970 Total Cash 133 M Next Fiscal Year End 1 B
Revenue Per Share 1.25 Held Percent Insiders 0.0615 Ebitda Margins -84.64 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 0.8758 Target Low Price 2.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.8351 Open 0.8800 Free Cashflow -72264496
State MA Dividend Yield 0.00 % Return On Assets -0.3427
Time Zone Short Name EST Trailing Eps -1.05 Day Low 0.8359
Address1 85 Wells Avenue Shares Outstanding 125 M Price Hint 4
Target High Price 7.00 Website https://www.karyopharm.com 52 Week Change 0.1078
Average Volume 754853 Forward Eps -0.7100 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 268.80 % Is_sp_500 False
Regular Market Day High 0.8800 Profit Margins -58.93 % Fifty Two Week High 1.95
Day High 0.8800 Shares Short 18 M Regular Market Open 0.8800
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 1.62
Revenue Growth 7.70 % Shares Percent Shares Out 0.1511 Operating Cashflow -120261000
Currency USD Time Zone Full Name America/New_York Market Cap 106 M
Is_nasdaq_100 False Zip 02459-3298 Quote Type EQUITY
Industry Biotechnology Long Name Karyopharm Therapeutics Inc. Regular Market Day Low 0.8359
Held Percent Institutions 0.5000 Current Price 0.8525 Address2 Suite 210
Enterprise To Ebitda -1.92 Financial Currency USD Current Ratio 3.00
Gross Margins 88.73 % Industry Disp Biotechnology Number Of Analyst Opinions 7
Country United States Float Shares 113 M Two Hundred Day Average 1.00
Enterprise Value 241 M Price To Sales Trailing12 Months 0.7197 Forward PE -1.13
Regular Market Volume 365673 Ebitda -125634000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds.

The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma.

Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.